tbuckley/cabot-search huggingface dataset:
Association of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic <i>CDKN2A</i> variants in patients with a poor prognosis
Authors: Okuto Iwasawa, Masachika Ikegami, Takuya Miyagawa, Hiromichi Morita, Hinako Saito, Issei Omori, Kentaro Awaji, Jun Omatsu, Daisuke Yamada, Hidenori Kage, Katsutoshi Oda, Shinichi Sato, Hayakazu Sumida
Journal: British Journal of Dermatology (2024)

Previous studies have reported the mutational landscape in extramammary Paget disease (EMPD); however, the prognostic implications of genetic alterations remain unexplored. While CDKN2A loss is known to be associated with tumour progression or poor prognosis in some types of cancer, its significance in EMPD has not been investigated.
Mapping tumor habitats in isocitrate dehydrogenase -wild type glioblastoma: Integrating MRI, pathologic, and RNA data from the Ivy Glioblastoma Atlas Project
Authors: Ji Eun Park, Joo Young Oh, Do Hoon Park, Ho-Su Lee, Shinkyo Yoon, NakYoung Kim, Seo Young Park, Sang Woo Song, Young-Hoon Kim, Chang-Ki Hong, Jeong Hoon Kim, Ho Sung Kim
Journal: Neuro-Oncology (2024)

Abstract Background The goal of the study was to spatially validate intratumoral subregions (tumor habitat) using physiologic magnetic resonance imaging (MRI) on the pathology of the isocitrate dehydrogenase (IDH)-wild-type whole-glioblastoma sample. Methods Data from 20 patients (168 slides) were obtained from the Ivy Glioblastoma Atlas Project. On MRI, tumor habitats were defined using voxel-wise clustering of the apparent diffusion coefficient and cerebral blood volume maps for contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). On pathology slides, normalized areas of leading-edge, infiltrating tumor (IT), cellular tumor (CT), hypervascular lesion (CThypervascular), and perinecrotic lesion (CTperinecrotic) were obtained. Gross specimen was coregistered on MRI and correlation between pathology-MRI habitats was calculated. RNA sequencing of 67 samples was assessed using 4 Neftel subtypes and further correlated with pathology. Results Six tumor habitats were identified: hypervascular, hypovascular cellular, and hypovascular hypocellular habitats for CEL and NEL. CT was correlated with hypovascular cellular habitat in CEL (r = 0.238, P = .005). IT was correlated with hypovascular cellular habitat in NEL (r = 0.294, P = .017). CThypervascular was correlated with hypervascular habitat in NEL (r = 0.195, P = .023). CTperinecrotic was correlated with imaging necrosis (r = 0.199, P = .005). Astrocyte-like subtypes were correlated with IT (r = 0.256, P &amp;lt; .001), while mesenchymal-like subtypes were correlated with CTperinecrotic area (r = 0.246, P &amp;lt; .001). Conclusions Pathologically matched tumor subregions were CT with hypovascular cellular habitat in CEL and infiltrative tumor with hypovascular cellular habitat in NEL. Identification of the most aggressive, as well as infiltrative tumor portion, can be achieved using noninvasive MRI tumor habitats.
Anti-ageing interventions for the treatment of cardiovascular disease
Authors: Mahmoud Abdellatif, Sophie T Schmid, Alexander Fuerlinger, Guido Kroemer
Journal: Cardiovascular Research (2024)

As the global demographic landscape continues to shift towards an aged population, so does the medical and socioeconomic burden of cardiovascular diseases. Indeed, ageing is one of, if not the, key risk factor for the development of cardiovascular diseases. However, there are currently no approved cardiovascular therapeutics that primarily target the molecular and cellular mechanisms underlying the ageing process itself. In this review, we present the potential of emerging anti-ageing strategies, including epigenetic rejuvenation, metabolic reprogramming, autophagy activation, as well as senolytic and anti-inflammatory therapies, in delaying or reversing the development of age-related cardiovascular disorders, while considering potential sex differences. In doing so, we implicate cellular ageing processes in the pathogenesis of several prevalent cardiovascular diseases, such as atherosclerosis, hypertension, various types of cardiomyopathies (including its hypertrophic, ischemic, dilated, diabetic, and arrhythmogenic forms) and heart failure, particularly that with preserved ejection fraction. Finally, we outline future challenges and steps needed for the implementation of these novel anti-ageing strategies in the clinical setting, with the aim of challenging the long-held notion of ageing as a 'nonmodifiable' risk factor for cardiovascular diseases.
Trajectories of cardiovascular ageing – from molecular mechanisms to clinical implementation
Authors: Stefano Ministrini, Florian A Wenzl, Thomas F Lüscher, Giovanni G Camici
Journal: Cardiovascular Research (2024)

Due to its peculiar structure and function, the cardiovascular system is particularly vulnerable to the detrimental effects of ageing. Current knowledge about the molecular mechanisms of ageing revealed the processes actively promoting ageing, e.g. progressive telomeres shortening, and the mechanisms opposing it, e.g. endogenous production of antioxidant substances. This knowledge can be used to measure biological age at a cellular and molecular level and to interfere with it by pharmacological or non-pharmacological interventions. Biological ageing is determined by the simultaneous occurrence of independent hallmarks, which encompass a wide range of biological processes, from genomic changes to systemic inflammation and dysbiosis. This narrative review will summarize the role of ageing hallmarks in the cardiovascular system, how they can be measured and what are the possible interventions to counteract their effects.
‘Psycholag’: a new term to describe the delay between physical and psychological improvement in patients with skin disease
Authors: Alia Ahmed, Padma Mohandas, Ruth Taylor, Iyas Assalman, Anthony Bewley
Journal: British Journal of Dermatology (2024)

Psycholag': a new term to describe the delay between physical and psychological improvement in patients with skin diseaseTreatment of chronic inflammatory skin conditions with systemic therapy has two facets: physical improvement and psychological recovery.The two appear connected, with severe skin disease sometimes (but not always) predicting more extensive psychological co-morbidities.The positive correlation of these two parameters on a biopsychosocial level seems self-explanatory.Treatment of systemic disease reduces disease burden, and as a result psychological improvement is experienced.However, it is rarely as simple as that.It has been demonstrated that despite clearance of skin disease, the long-term psychological sequalae of skin conditions may persist. 1 Using the concept of jet lag; when the body travels across different time zones, the individual's circadian rhythm is linked to the original time zone and it takes time for those rhythms to 'catch up' to the destination.Where an individual experiences physical resolution rapidly with systemic treatments, research has indicated that there may be a period of delay before the psychological symptoms experienced by the patient improve.We are coining this phenomenon 'psycholag'.Psycholag has been observed in psoriasis, where feelings of loss of control, social withdrawal and impact on self-image have all been seen to lag behind the rapid physical skin changes experienced with the use of biologics and small molecule therapies. 1Similarly, patients with atopic dermatitis treated with biologics do not report psychological improvement in tandem with physical improvements in the longer term, and this is even less likely in females with later disease onset. 2 Furthermore in psychiatric disease, we note that in cases of depression, despite effective treatment for symptoms, people tend to experience delay in tangible psychological improvements.
A reporter system for live cell tracking of human cardiomyocyte proliferation
Authors: Alessia Costa, Hannah Jill Hunkler, Shambhabi Chatterjee, Sarah Cushman, Erika Hilbold, Ke Xiao, Dongchao Lu, Julia Leonardy, Malte Juchem, Marida Sansonetti, Jeannine Hoepfner, Thomas Thum, Christian Bär
Journal: Cardiovascular Research (2024)
An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
Authors: Carla M. Nester, David L. Feldman, Richard Burwick, Spero Cataland, Shruti Chaturvedi, H. Terence Cook, Adam Cuker, Bradley P. Dixon, Fadi Fakhouri, Sangeeta R. Hingorani, Anuja Java, Nicole C.A.J. van de Kar, David Kavanagh, Nelson Leung, Christoph Licht, Marina Noris, Michelle M. O’Shaughnessy, Samir V. Parikh, Flora Peyandi, Giuseppe Remuzzi, Richard J.H. Smith, C. John Sperati, Meryl Waldman, Patrick Walker, Marina Vivarelli
Journal: Kidney International (2024)

The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin–associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
Near Infrared‐Triggered Nitric Oxide‐Release Nanovesicles with Mild‐Photothermal Antibacterial and Immunomodulation for Healing MRSA‐Infected Diabetic Wounds
Authors: Chang Xu, Jiqing Zhang, Junxian Zhang, Danting Li, Xiaozhe Yan, Yuxuan Gu, Meihui Zhong, Hui Gao, Qiang Zhao, Xiongwei Qu, Pingsheng Huang, Jimin Zhang
Journal: Advanced Healthcare Materials (2024)

Abstract Bacterial infection‐induced excessive inflammation is a major obstacle in diabetic wound healing. Nitric oxide (NO) exhibits significant antibacterial activity but is extremely deficient in diabetes. Hence, a near‐infrared (NIR)‐triggered NO release system is constructed through codelivery of polyarginine (PArg) and gold nanorods (Au) in an NIR‐activatable methylene blue (MB) polypeptide‐assembled nanovesicle (Au/PEL‐PBA‐MB/PArg). Upon NIR irradiation, the quenched MB in the nanovesicles is photoactivated to generate more reactive oxygen species (ROS) to oxidize PArg and release NO in an on‐demand controlled manner. With the specific bacterial capture of phenylboronic acid (PBA), NO elevated membrane permeability and boosted bacterial vulnerability in the photothermal therapy (PTT) of the Au nanorods, which is displayed by superior mild PTT antibacterial activity against methicillin‐resistant Staphylococcus aureus (MRSA) at temperatures &lt; 49.7 °C in vitro. Moreover, in vivo, the antibacterial nanovesicles greatly suppressed the burst of MRSA‐induced excessive inflammation, NO relayed immunomodulated macrophage polarization from M1 to M2, and the excessive inflammatory phase is successfully transferred to the repair phase. In cooperation with angiogenesis by NO, tissue regeneration is accelerated in MRSA‐infected diabetic wounds. Therefore, nanoplatform has considerable potential for accelerating the healing of infected diabetic wounds.
Programmed surface platform orchestrates anti-bacterial ability and time-sequential bone healing for implant-associated infection
Authors: Zhou Yu, Zhaolong Wang, Yitong Chen, Yuchen Wang, Like Tang, Yue Xi, Kaichen Lai, Qi Zhang, Shuangyang Li, Danyu Xu, Anrong Tian, Mengjie Wu, Ying Wang, Guoli Yang, Changyou Gao, Tingben Huang
Journal: Biomaterials (2024)
Comparative Effectiveness of Dupilumab and Omalizumab on Asthma Exacerbations and Systemic Corticosteroid Prescriptions: Real-World US ADVANTAGE Study
Authors: Eugene Bleecker, Michael Blaiss, Juby Jacob-Nara, Lynn Huynh, Mei Sheng Duh, Tracy Guo, Mingchen Ye, Richard H. Stanford, Zhixiao Wang, Xavier Soler, Arpita Nag, Radhika Nair, Kinga Borsos
Journal: Journal of Allergy and Clinical Immunology (2024)

In the United States, dupilumab is approved for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma, and omalizumab is approved for managing moderate-to-severe allergic asthma uncontrolled by inhaled corticosteroids. However, limited comparative effectiveness data exist for these biologics due to differing patient characteristics and treatment histories.
The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-22 influenza season
Authors: Hélène Bricout, Marie-Cécile Levant, Nada Assi, Pascal Crépey, Alexandre Descamps, Karine Mari, Jacques Gaillat, Gaétan Gavazzi, Benjamin Grenier, Odile Launay, Anne Mosnier, Fanny Raguideau, Laurence Watier, Rebecca C. Harris, Ayman Chit
Journal: Clinical Microbiology and Infection (2024)

ObjectivesHigh-dose quadrivalent influenza vaccine (HD-QIV) was introduced during the 2021/22 influenza season in France for adults aged ≥65 years as an alternative to standard-dose quadrivalent influenza vaccines (SD-QIV). The aim of this study is to estimate the relative vaccine effectiveness (rVE) of HD-QIV versus SD-QIV against influenza-related hospitalisations in France.MethodsCommunity-dwelling individuals aged ≥65 years with reimbursed influenza vaccine claims during the 2021/22 influenza season were included from the French national health insurance database. Individuals were followed up from vaccination day to 30 June 2022, nursing home admission or death date. Baseline socio-demographic and health characteristics were identified from medical records over the five previous years. Hospitalisations due to influenza and other causes were recorded from 14 days after vaccination to end of follow-up. HD-QIV and SD-QIV vaccinees were matched using 1:4 propensity score matching with an exact constraint on age group, sex, week of vaccination and region. Incidence rate ratios (IRR) were estimated using zero-inflated Poisson or zero-inflated negative binomial regression models.ResultsWe matched 405,385 HD-QIV to 1,621,540 SD-QIV vaccinees. HD-QIV was associated with a 23.3% (95%CI: 8.4–35.8) lower rate of influenza hospitalisations compared with SD-QIV (69.5/100,000 person-years (PY) vs 90.5/100,000 py). Post-matching, we observed higher rates in the HD-QIV group for hospitalisations non-specific to influenza and for negative control outcomes, suggesting residual confounding by indication.ConclusionsHD-QIV was associated with lower influenza-related hospitalisation rates versus SD-QIV, consistent with existing evidence, in the context of high SARS-CoV-2 circulation in France and likely prioritisation of HD-QIV for older/more comorbid individuals.
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Authors: Roger Li, Patrick J Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Peter C Black, Maurizio Brausi, Kelly K Bree, Mario I Fernández, Charles C Guo, Amir Horowitz, Donald L Lamm, Seth P Lerner, Yair Lotan, Paramananthan Mariappan, David McConkey, Laura S Mertens, Carmen Mir, Jeffrey S Ross, Michael O'Donnell, Joan Palou, Kamal Pohar, Gary Steinberg, Mark Soloway, Philippe E Spiess, Robert S Svatek, Wei Shen Tan, Rikiya Taoka, Roger Buckley, Ashish M Kamat
Journal: European Urology (2024)
Prostate Cancer Early Detection in the European Union and UK
Authors: Renée C A Leenen, Lionne D F Venderbos, Jozien Helleman, Juan Gómez Rivas, Pieter Vynckier, Lieven Annemans, Renata Chloupková, Ondřej Májek, Erik Briers, Vera Vasilyeva, Sebastiaan Remmers, Meike J van Harten, Frederique B Denijs, Ivo I de Vos, Arunah Chandran, Partha Basu, Roderick C N van den Bergh, Sarah Collen, Hein Van Poppel, Monique J Roobol, Katharina Beyer
Journal: European Urology (2024)

While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK.
Geographical distribution of the Cryptococcus gattii species complex: a systematic review
Authors: Victoria Poplin, Clarissa Smith, Diego H Caceres, Patricia F Herkert, Olujimi Jegede, George R Thompson, John W Baddley, Ilan S Schwartz, Ryan Kubat, Mark A Deka, Mitsuru Toda, Shawn R Lockhart, Tom Chiller, Ferry Hagen, Nathan C Bahr
Journal: The Lancet Microbe (2024)

The taxonomy of the Cryptococcus gattii species complex continues to evolve, and has been divided into five pathogenic species. The objective of this systematic review was to summarise the geographical distribution of the C gattii species complex and the species within the C gattii species complex. We searched PubMed for articles related to human, animal, ecological, or laboratory-based studies of C gattii species complex isolates with traceable geographical origin published from January, 1970, until September, 2021. Having extracted their geographical origin, we used ArcMap to construct maps according to the highest degree of resolution allowed by their reported taxonomy, to reflect the most likely area of transmission on the basis of published reports of human isolates. 604 such articles were included in the study. This review indicated that although C gattii species complex isolates have been reported globally, understanding their heterogeneous geographical distribution by species can have implications for researchers and clinicians in formulating research questions and considering diagnostic quandaries.
Combination topical 5-fluorouracil 5%/calcipotriene 0.005% cream for the treatment of cutaneous in situ squamous cell carcinoma: a pilot study
Authors: Riya T Patel, Kiley K Fagan, Eugenie Y Quan, Nathan M Johnson, Allison N Tegge, Alex C Holliday, Douglas J Grider, Patrick S Rush, Kyle A Prickett, Joshua D Eikenberg, Mariana A Phillips
Journal: Journal of the American Academy of Dermatology (2024)
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review
Authors: Siddhartha Sood, Alexander Rimke, Brian D Rankin, Abrahim Abduelmula, Jorge R Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Alim R Devani, Ronald Vender, Jensen Yeung, Vimal H Prajapati
Journal: Journal of the American Academy of Dermatology (2024)
Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplasty
Authors: J William Tierney, R Paolo Francisco, Fang Yu, Jinqi Ma, Joyce Cheung-Flynn, Megan C Keech, Richard D'Arcy, Veeraj M Shah, Anna R Kittel, Devin J Chang, Joshua T McCune, Mariah G Bezold, Adrian N Aligwekwe, Rebecca S Cook, Joshua A Beckman, Colleen M Brophy, Craig L Duvall
Journal: Biomaterials (2024)

Peripheral artery disease is commonly treated with balloon angioplasty, a procedure involving minimally invasive, transluminal insertion of a catheter to the site of stenosis, where a balloon is inflated to open the blockage, restoring blood flow. However, peripheral angioplasty has a high rate of restenosis, limiting long-term patency. Therefore, angioplasty is sometimes paired with delivery of cytotoxic drugs like paclitaxel to reduce neointimal tissue formation. We pursue intravascular drug delivery strategies that target the underlying cause of restenosis - intimal hyperplasia resulting from stress-induced vascular smooth muscle cell switching from the healthy contractile into a pathological synthetic phenotype. We have established MAPKAP kinase 2 (MK2) as a driver of this phenotype switch and seek to establish convective and contact transfer (coated balloon) methods for MK2 inhibitory peptide delivery to sites of angioplasty. Using a flow loop bioreactor, we showed MK2 inhibition in ex vivo arteries suppresses smooth muscle cell phenotype switching while preserving vessel contractility. A rat carotid artery balloon injury model demonstrated inhibition of intimal hyperplasia following MK2i coated balloon treatment in vivo. These studies establish both convective and drug coated balloon strategies as promising approaches for intravascular delivery of MK2 inhibitory formulations to improve efficacy of balloon angioplasty.
Delay in diagnosis and undertreatment of lichen sclerosus in pediatric male patients: A retrospective case series
Authors: Anjie Ge, Jacob P. Reinhart, Dawn M.R. Davis, Megha M. Tollefson, Rochelle R. Torgerson, Anthony J. Mancini, Nessa Aghazadeh Mohandesi
Journal: Journal of the American Academy of Dermatology (2024)
Impact of TAS2R38 polymorphisms on nasal nitric oxide and<i>Pseudomonas</i>infections in primary ciliary dyskinesia: relation to genotype
Authors: Massimo Pifferi, Attilio Boner, Debora Maj, Angela Michelucci, Gabriele Donzelli, Angela M Cangiotti, Raffaella Guazzo, Giulia Bertolucci, Veronica Bertini, Chiara Doccioli, Michele Piazza, Angelo Valetto, Maria Adelaide Caligo, Diego Peroni, Andrew Bush
Journal: Thorax (2024)

Objective Primary ciliary dyskinesia (PCD) severity has been related to genotype and levels of nasal nitric oxide (nNO). The most common TAS2R38 haplotypes (PAV/PAV, PAV/AVI, AVI/AVI) encoding the bitter taste receptor can affect nNO levels and thus could play a role in the susceptibility to respiratory infections. We assessed the impact of these polymorphisms on nNO production and Pseudomonas aeruginosa ( P.a .) infections in different PCD genotypes. Methods Prospective, longitudinal, single-centre study in patients with PCD with known genotype and one of three TAS2R38 haplotypes evaluated for up to 10 years. We related nNO values to TAS2R38 haplotypes in all patients, and in the three most frequent genotypes ( CCDC39/CCDC40 , DNAH5 , DNAH11 ). In the genetic group(s) with different mean trends of nNO in relation to the polymorphism, we evaluated longitudinal lung function as a clinical outcome measure. We also studied any associations between the prevalence of chronic P.a . infection and PAV alleles. Linear mixed-effects models were used to evaluate longitudinal associations. Results 119 patients with PCD underwent 1116 study visits. Only in the DNAH11 mutations group was there a mean trend of nNO production which was significantly higher in PAV/PAV than AVI/AVI haplotype (p=0.033), with a better trend in spirometric and plethysmographic parameters. In patients with DNAH11 mutations the PAV allele was also associated with a significantly reduced prevalence of chronic P.a . infection. Conclusion TAS2R38 may be a modifier gene for PCD severity, but only in mild phenotype disease. Further study of TAS2R38 polymorphisms might enable new management strategies to prevent chronic P.a . infections.
Alginate-based artificial antigen presenting cells expand functional CD8+ T cells with memory characteristics for adoptive cell therapy
Authors: Mary O Omotoso, Savannah E Est-Witte, Sydney R Shannon, Shuyi Li, Nina M Nair, Sarah Y Neshat, Si-Sim Kang, Stephany Y Tzeng, Jordan J Green, Jonathan P Schneck
Journal: Biomaterials (2024)
CRISPR-AMRtracker: a novel toolkit to monitor the antimicrobial resistance gene transfer in fecal microbiota
Authors: Gong Li, Teng-Fei Long, Shi-Ying Zhou, Li-Juan Xia, Ang Gao, Lei Wan, Xiao-Yuan Diao, Yu-Zhang He, Ruan-Yang Sun, Jin-Tao Yang, Sheng-Qiu Tang, Hao Ren, Liang-Xing Fang, Xiao-Ping Liao, Ya-Hong Liu, Liang Chen, Jian Sun
Journal: Drug Resistance Updates (2024)